DRUG · Unmapped registry intervention
BB-1701
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
BB-1701DRUG
Sponsors & collaborators
Eisai Inc.lead sponsor
Bliss Biopharmaceutical (Hangzhou) Co., Ltdcollaborator
Mapped research locations
ClevelandOhio, United States3MadridSpain2New YorkNew York, United States1Los AngelesCalifornia, United States1St LouisMissouri, United States1San FranciscoCalifornia, United States1BarcelonaSpain1PittsburghPennsylvania, United States1TampaFlorida, United States1IndianapolisIndiana, United States1OrlandoFlorida, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06188559 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.